Skip to main content
. 2018 Nov 23;108(5):933–945. doi: 10.1093/ajcn/nqy196

TABLE 2.

Preselected genes with significant differences (uncorrected Poverall < 0.05) in expression levels1

Gene symbol Mean FC2 FC differences P value
Address ID ICR CCR Control ICR-CCR ICR-Control CCR-Control Uncorrected3 Corrected4
7330035 SFRP4 secreted frizzled-related protein 4 −0.13 ± 0.03 −0.05 ± 0.03 0.01 ± 0.03 −0.08 ± 0.04 −0.15 ± 0.05 −0.06 ± 0.04 0.003 0.24
6450672 VEGFA vascular endothelial growth factor A 0.01 ± 0.01 −0.05 ± 0.01 0.01 ± 0.02 0.06 ± 0.02 0.00 ± 0.02 −0.06 ± 0.02 0.01 1
3940017 LOX lysyl oxidase −0.23 ± 0.05 −0.08 ± 0.05 −0.04 ± 0.05 −0.15 ± 0.07 −0.19 ± 0.07 −0.04 ± 0.07 0.02 1
3610129 HSD17B1 hydroxysteroid(17-β)dehydrogenase1 −0.09 ± 0.02 0.02 ± 0.03 −0.06 ± 0.03 −0.10 ± 0.03 −0.03 ± 0.04 0.07 ± 0.04 0.02 1
1980309 IL8 interleukin 8 0.12 ± 0.16 −0.49 ± 0.16 0.03 ± 0.18 0.61 ± 0.23 0.09 ± 0.24 −0.51 ± 0.24 0.02 1
2640543 SFRP4 secreted frizzled-related protein 4 −0.22 ± 0.07 −0.10 ± 0.06 0.02 ± 0.07 −0.12 ± 0.09 −0.24 ± 0.10 −0.12 ± 0.09 0.03 1
4050022 TSHR thyroid stimulating hormone receptor 0.03 ± 0.02 −0.03 ± 0.02 −0.01 ± 0.01 0.06 ± 0.02 0.04 ± 0.02 −0.03 ± 0.02 0.03 1
2900129 FTO fat mass and obesity associated −0.05 ± 0.03 0.05 ± 0.02 0.00 ± 0.02 −0.10 ± 0.04 −0.04 ± 0.04 0.05 ± 0.03 0.03 1
2680056 CES1 carboxylesterase 1 −0.43 ± 0.07 −0.19 ± 0.08 −0.32 ± 0.07 −0.25 ± 0.10 −0.12 ± 0.10 0.13 ± 0.10 0.03 1
7330544 ALDOC aldolase C, fructose-bisphosphate −0.40 ± 0.07 −0.31 ± 0.09 −0.16 ± 0.06 −0.09 ± 0.11 −0.24 ± 0.09 −0.15 ± 0.11 0.04 1
3710523 CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 −0.05 ± 0.02 −0.01 ± 0.02 0.02 ± 0.02 −0.04 ± 0.03 −0.07 ± 0.03 −0.03 ± 0.03 0.04 1
1570553 IL8 interleukin 8 −0.02 ± 0.08 −0.25 ± 0.08 0.00 ± 0.08 0.23 ± 0.11 −0.01 ± 0.12 −0.24 ± 0.11 0.04 1
840309 LEP leptin −0.23 ± 0.06 −0.05 ± 0.05 −0.14 ± 0.04 −0.18 ± 0.07 −0.09 ± 0.07 0.08 ± 0.06 0.04 1

1Data were included from 150 participants; statistical analyses were performed with the use of an intention-to-treat approach. CCR, continuous calorie restriction; FC, fold change; ICR, intermittent calorie restriction.

2Mean log FCs ± SEs within groups were calculated as differences between the expression levels at baseline (T0) and the expression levels at week 12 (T1): log2(FC) = log2(T1/T0).

3 Pvalues for time-by-treatment interactions across all 3 study groups were calculated with linear mixed models adjusted for age and sex. No adjustment was made for multiple comparisons. P values for post hoc pairwise comparisons between individual study groups are shown in Supplemental Table 2.

4 P values for time-by-treatment interactions across all 3 study groups were calculated with linear mixed models adjusted for age and sex including Bonferroni correction for multiple comparisons (P values were multiplied by the number of genes, i.e., by 82).